[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pusan National University Yangsan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":574},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,43,69,96,117,142,168,186,207,235,260,284,308,337,357,377,396,416,434,453,474,496,515,531,552],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640236","response-surface-modeling-of-remimazolam-and-sevoflurane-100640236",false,"NCT07620782","Response Surface Modeling of Remimazolam and Sevoflurane","Response Surface Model Between Remimazolam and Sevoflurane; Comparison of the Minto and the Greco Model","Inclusion Criteria:\n\n* Adults aged 20 to 80 years\n* Scheduled for elective surgery under general anesthesia at Pusan National University Yangsan Hospital\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy to remimazolam or sevoflurane\n* Renal, hepatic, neuromuscular, or neurological disease\n* Use of medications affecting the central nervous system\n* Chronic psychoactive drug use\n* Ischemic heart disease\n* Pregnant women","ALL","20 Years","80 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective randomized open-label study aims to investigate the pharmacodynamic interaction between remimazolam and sevoflurane during general anesthesia using response surface modeling. Although remimazolam has favorable hemodynamic stability compared with propofol, its hypnotic effect may be less predictable and poorly correlated with conventional sedation monitoring indices such as the bispectral index (BIS). In clinical practice, remimazolam and sevoflurane are often combined during induction and maintenance of anesthesia; however, the optimal interaction between these agents remains unclear.\n\nThis study will evaluate whether the interaction between remimazolam and sevoflurane is synergistic, additive, or infra-additive using two representative response surface interaction models: the Minto model and the Greco model. BIS values and predicted effect-site concentrations will be analyzed using NONMEM software.",[27],"Laparoscopic Surgery",[29],"general anesthesia","RECRUITING","2026-05-27",{"date":33,"type":34},"2026-06-02","ACTUAL",{"date":36,"type":34},"2026-05-15",{"date":38,"type":21},"2027-12-31",{"name":40,"class":41},"Pusan National University Yangsan Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100632280","comparison-of-sevoflurane-and-desflurane-on-ani-in-patients-undergoing-general-anesthesia-a-prospective-randomized-controlled-study-100632280","NCT07511634","Comparison of Sevoflurane and Desflurane on ANI in Patients Undergoing General Anesthesia: a Prospective Randomized Controlled Study","Inclusion Criteria:\n\n* Adults aged 19 to 79 years\n* Patients undergoing general anesthesia\n* American Society of Anesthesiologists (ASA) physical status I or II\n\nExclusion Criteria:\n\n* History of taking medications that may affect the central nervous system or autonomic nervous system (e.g., anticholinergics, beta-blockers, antidepressants, anxiolytics, hypnotics, or analgesics)\n* Known hypersensitivity to sevoflurane, desflurane, or other halogenated anesthetics, or a personal or family history of malignant hyperthermia\n* Neurologic or psychiatric disorders (e.g., depression, dementia, or cerebral infarction)\n* Arrhythmia\n* Diabetes mellitus\n* Drug abuse or alcohol abuse\n* Vulnerable subjects\n* Patients aged 80 years or older\n* Patients with impaired consciousness or those judged to lack the capacity to provide informed consent","19 Years","79 Years",{"count":20,"type":21},[24],"This prospective randomized controlled study will compare the effects of sevoflurane and desflurane on the Analgesia Nociception Index (ANI) in adult patients undergoing general anesthesia. Participants will be randomized to maintenance anesthesia with either sevoflurane or desflurane, and ANI responses to a standardized nociceptive stimulus will be measured under equi-minimum alveolar concentration (age-adjusted 1.0 MAC) conditions. The primary objective is to compare the change in ANI before and after tetanic stimulation between the two anesthetic groups. Secondary measurements will include bispectral index, blood pressure, heart rate, and end-tidal anesthetic concentration around the time of stimulation.",[55],"General Anesthesia",[57,58,59],"Analgesia Nociception Index","ANI","Sevoflurane","NOT_YET_RECRUITING","2026-03-30",{"date":63,"type":34},"2026-04-06",{"date":65,"type":21},"2026-04-01",{"date":67,"type":21},"2026-12-31",{"name":40,"class":41},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":95,"locationsCount":4},"100618646","extracorporeal-blood-purification-using-oxiris-for-septic-shock-explore-study-100618646","NCT07334327","Extracorporeal Blood Purification Using Oxiris for Septic Shock (EXPLORE Study)","Efficacy of eXtracorPoreal bLOod puRification Using oXiris in Patients With SEptic Shock: A Multicenter Propensity-matched Cohort Study (EXPOLRE Study)","EXPOLRE","Inclusion Criteria:\n\n* Participants must be 19 years of age or older.\n* Participants must be diagnosed with septic shock (a severe body-wide response to infection that leads to dangerously low blood pressure).\n* Participants must be in a condition where the medical team has decided that blood purification therapy (like CRRT) is necessary.\n\nExclusion Criteria:\n\n* People who have a \"Do Not Resuscitate\" (DNR) order or are not expected to survive more than 24 hours.\n* People who are pregnant or breastfeeding.\n* People who are known to be allergic to the materials used in the Oxiris filter (such as heparin or specific plastics).\n* People who are already participating in another clinical trial that might affect the results of this study.\n* People whom the doctor decides are not suitable for the study for other medical safety reasons.",{"count":78,"type":21},62,[24],"The goal of this clinical trial is to evaluate if a blood purification treatment called \"Oxiris\" works to help adults with septic shock. The main questions it aims to answer are: (1) Does Oxiris treatment lower the risk of death or organ failure within the first 7 days? (2) Does Oxiris treatment lower the level of inflammation in the body? Researchers will compare participants who receive Oxiris treatment to a group of participants who receive standard medical care to see if Oxiris helps them recover better.\n\nParticipants will:\n\n1. Receive blood purification therapy using the Oxiris filter for up to 3 days while in the intensive care unit (ICU).\n2. Have their blood tested at the start of the study and 3 days later to check for inflammation and organ function.\n3. Be followed by the research team for about 30 days to check on their health and recovery.",[82,83],"Septic Shock","Multi Organ Failure",[85,86,87,88],"Septic shock","multi organ failure","blood purification","cytokine","2026-01-12",{"date":91,"type":34},"2026-01-14",{"date":93,"type":21},"2026-02-01",{"date":38,"type":21},{"name":40,"class":41},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100532337","autonomic-dysreflexia-in-spinal-cord-injuries-uds-filling-speed-impact-100532337","NCT06211491","Autonomic Dysreflexia in Spinal Cord Injuries: UDS Filling Speed Impact","Autonomic Dysreflexia Clinical Characteristics According to the Filling Speed in Urodynamics in Individuals With Spinal Cord Injuries","Inclusion Criteria:\n\n1. Patients with chronic spinal cord injury 6 months after receiving the award\n2. Patients with confirmed AD due to bladder fullness in previous urodynamic test\n3. Patients confirmed to have neurological damage level C1-T6, AIS A or B\n\nExclusion Criteria:\n\n1. Patients who cannot perform the test because their systolic blood pressure remains at 150 mmHg during the urodynamic test\n2. Patients who cannot undergo testing due to hemodynamic instability\n3. Patients who cannot undergo testing due to overt urinary tract infection",{"count":104,"type":21},30,"OBSERVATIONAL","In patients with spinal cord injury, the investigators want to understand and understand the differences in AD prevalence and characteristics according to bladder injection rate, and to determine which factors have a greater influence between bladder expansion or injection rate.",[108,109,110],"Spinal Cord Injuries","Autonomic Dysreflexia","UDS Filling Speed",{"date":91,"type":34},{"date":113,"type":34},"2025-01-08",{"date":115,"type":21},"2026-12-30",{"name":40,"class":41},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":42},"100618649","broccoli-sprout-extract-for-cognitive-function-100618649","NCT07334366","Broccoli Sprout Extract for Cognitive Function","A 12-week Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Broccoli Sprout Extract on Cognitive Function Improvement in Adults With Mild Cognitive Impairment","Inclusion Criteria:\n\n* Age: Adults aged 55-85 years (inclusive), both male and female\n* Global Deterioration Scale (GDS) score of 2-3:\n\nGDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment\n\n* Absence of dementia according to established diagnostic criteria\n* Ability to read Korean\n\nExclusion Criteria:\n\n* Severe medical conditions within the past 6 months: History of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignancy (Note: Participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion)\n* Cognitive impairment-associated diseases: Dementia, Parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline Uncontrolled hypertension: Blood pressure ≥160\u002F100 mmHg (measured after 10 minutes of rest)\n* Poor glycemic control: Fasting blood glucose ≥160 mg\u002FdL in diabetic patients\n* Uncontrolled thyroid dysfunction: Currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism\n* Renal impairment: Serum creatinine ≥2 times the upper limit of normal for the institution\n* Hepatic impairment: AST or ALT ≥2 times the upper limit of normal for the institution\n* Severe gastrointestinal symptoms: Complaints of severe heartburn, dyspepsia, or other gastrointestinal distress\n* Medications affecting cognitive function within the past month: Use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities\n* Other clinical trial participation: Participation in other drug clinical trials within the past month or planned participation during the study period\n* Alcohol use disorder, severe\n* Food allergies: Known allergic reactions to study product components\n* Investigator discretion: Any other condition deemed inappropriate for study participation by the investigator","50 Years","85 Years",{"count":127,"type":21},100,[24],"This clinical trial aims to determine whether broccoli sprout extract improves cognitive function in adults with mild cognitive impairment and to assess its safety.\n\nThe main questions are:\n\n* Does broccoli sprout extract improve cognitive function in participants?\n* What side effects occur when participants take broccoli sprout extract?",[131,132],"Cognitive Dysfunction","Cognitive Decline",[134],"cognition","2026-01-11",{"date":137,"type":34},"2026-01-13",{"date":139,"type":34},"2025-04-16",{"date":67,"type":21},{"name":40,"class":41},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":167,"locationsCount":42},"100619649","electromagnetic-high-frequency-chest-wall-oscillation-on-pulmonary-mucus-clearance-in-patients-with-impaired-self-expectoration-100619649","NCT07347366","Electromagnetic High-Frequency Chest Wall Oscillation on Pulmonary Mucus Clearance in Patients With Impaired Self-Expectoration","Effects of Electromagnetic High-Frequency Chest Wall Oscillation on Pulmonary Mucus Clearance in Patients With Impaired Self-Expectoration: An Investigator-Initiated, Single-Center, Prospective, Exploratory Study","Inclusion Criteria:\n\n* Hospitalized patients who require sputum clearance.\n* Patients who present with fever or respiratory symptoms (cough, sputum) and, after confirmation of findings on imaging studies, are judged by the clinician to require sputum clearance.\n* Adult patients (≥ 18 years) who have signed the informed consent form, or patients for whom consent has been obtained from a legally authorized representative\n\nExclusion Criteria:\n\n* Patients with severe pneumonia requiring intensive care unit (ICU) treatment.\n* Patients with major pulmonary diseases other than pneumonia, such as active tuberculosis or lung cancer.\n* Patients with severe respiratory failure (PaO₂\u002FFiO₂ ≤ 200 mmHg).\n* Patients with hemodynamically unstable cardiovascular disease (myocardial infarction within the past 3 months, or heart failure of NYHA class 3 or higher).\n* Patients hospitalized for head and neck trauma whose surgical site has not yet healed.\n* Patients with serious cardiac arrhythmias or hemodynamic instability.\n* Patients who have had pneumothorax or massive hemoptysis within the past 6 months, or who currently have hemoptysis.\n* Patients who have undergone spinal surgery within the past 6 months or who have acute spinal injury.\n* Patients with osteoporosis.\n* Patients with bronchopleural fistula.\n* Pregnant or breastfeeding women.\n* Patients diagnosed with cervical disc disease.\n* Individuals who have participated in clinical studies two or more times in the same year, or who have participated in another clinical study within the past 6 months (however, patients enrolled in chronic lung disease cohort studies such as asthma or COPD are allowed).\n* Individuals who, in the judgment of the principal investigator or sub-investigator, have clinically significant findings that make them unsuitable for participation in this study","18 Years",{"count":151,"type":21},45,[24],"This exploratory study aims to evaluate the efficacy and safety of an electromagnetic high-frequency, low-strain chest wall oscillation device for enhancing pulm",[155],"Sputum",[157,158,159,160],"sputum clearance","respiratory symptoms","Pulmonary Mucus Clearance","Electromagnetic High-Frequency Chest Wall Oscillation","2026-01-08",{"date":163,"type":34},"2026-01-16",{"date":165,"type":34},"2025-09-23",{"date":67,"type":21},{"name":40,"class":41},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":4},"100619681","ai-based-speech-intelligibility-assessment-efficacy--reliability-100619681","NCT07347782","AI-Based Speech Intelligibility Assessment: Efficacy & Reliability","Clinical Study on the Efficacy and Reliability of Speech Intelligibility Assessment for Post-stroke Patients Using an AI Solution","AI Solution","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Patients with neurologic disorders, including amyotrophic lateral sclerosis, poliomyelitis, cerebellar disorders, cerebellar lesions, and stroke.\n* Patients presenting with concomitant speech disorders, such as dysarthria, motor speech disorders, and voice disorders.\n\nExclusion Criteria:\n\n* Subjects with a score of less than 16 points on the Korean Mini-Mental State Examination (K-MMSE).\n* Subjects with visual, perceptual, or auditory impairments that prevent them from following the examiner's instructions.\n* Subjects judged by the researcher as unsuitable for participation in this clinical study due to other reasons.",{"count":177,"type":21},40,"compare the auditory-perceptual assessment conducted by speech-language pathologists using the U-TAP with the assessment performed via the AI solution (Blings) program in patients with speech disorders, and to evaluate the efficacy and reliability of these two methods for speech intelligibility assessment.",[180],"Patients With Speech Disorders",{"date":163,"type":34},{"date":183,"type":21},"2026-02",{"date":67,"type":21},{"name":40,"class":41},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":18,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":206,"locationsCount":4},"100617838","the-effect-of-pbm-on-the-electrical-activity-of-the-brain-in-stroke-patients-100617838","NCT07323823","The Effect of PBM on the Electrical Activity of the Brain in Stroke Patients","The Effect of 850 nm Photobiomodulation Therapy (PBM) on the Electrical Activity of the Brain in Stroke Patients","PBM","Inclusion Criteria:\n\n* Patients diagnosed with ischemic or hemorrhagic stroke by a specialist. Patients in the recovery phase within 1 year after onset; those with confirmed clinical functional impairment upon assessment, who are conscious and able to cooperate with PBM stimulation and evaluations.\n\nAdult patients (≥ 18 years old) ，less than 80 years old，who have signed the informed consent form, or patients with proxy consent.\n\nExclusion Criteria:\n\n* Individuals with photosensitive skin at risk of developing urticaria or dermatitis.\n\nPatients judged to have an unstable surgical site following hemorrhagic stroke-related surgery.\n\nPregnant or lactating individuals. Individuals with a history of seizures. Individuals who have participated in clinical studies twice or more in the same year or in other clinical studies within 6 months.\n\nOther individuals with clinically significant findings deemed medically inappropriate for the study by the principal investigator or responsible researcher.",{"count":195,"type":21},66,[24],"The Effect of Low-Level Light Therapy on the Electrical Activity of the Brain in Stroke Patients",[199],"Post-stroke Aphasia","2025-12-23",{"date":202,"type":34},"2026-01-07",{"date":204,"type":21},"2025-12-31",{"date":67,"type":21},{"name":40,"class":41},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":214,"sex":16,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":233,"leadSponsor":234,"locationsCount":42},"100617869","effects-of-combined-heat-application-and-acupressure-to-the-carotid-artery-region-on-cerebral-blood-flow-in-healthy-adults-100617869","NCT07324226","Effects of Combined Heat Application and Acupressure to the Carotid Artery Region on Cerebral Blood Flow in Healthy Adults","Effects of Combined Heat Application and Acupressure to the Carotid Artery Region on Cerebral Blood Flow in Healthy Adults: An Investigator-Initiated, Single-Group, Single-Center, Prospective Case Study","Inclusion Criteria:\n\n* Adults aged 40 to 65 years.\n* Individuals with no history of cerebrovascular, cardiovascular, or neurological diseases.\n* Individuals who have signed the informed consent form and voluntarily agreed to participate in the study\n\nExclusion Criteria:\n\n* Individuals with a history of cerebrovascular, cardiovascular, or neurological diseases (e.g., stroke, angina, epilepsy).\n\nIndividuals currently taking medications that may affect cerebral blood flow (such as antihypertensive agents or antidepressants).\n\nIndividuals with skin diseases or lesions that make it difficult to apply heat or acupressure devices to the carotid artery region, and individuals who are pregnant or breastfeeding.\n\nIndividuals with a history of seizures.\n\nIndividuals who have participated in clinical studies two or more times in the same year, or who have participated in another clinical study within the past 6 months.\n\nIndividuals who, in the judgment of the principal investigator or sub-investigator, have clinically significant findings that make them unsuitable for participation in this study.",true,"40 Years","65 Years",{"count":218,"type":21},9,[24],"The aim of this study is to investigate the effects of combined heat application and acupressure to the carotid artery region on cerebral blood flow in healthy adults",[222],"Healthy Subjects\u002FVolunteers",[224,225,226,227,228,229,230],"Carotid artery","Heat application","SPECT imaging","Acupressure Combined heat and acupressure","Cerebral blood flow","Single-group prospective study","Single-center study",{"date":202,"type":34},{"date":93,"type":21},{"date":67,"type":21},{"name":40,"class":41},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":192,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":42},"100613848","whole-body-photobiomodulation-for-motor-and-cognitive-changes-in-parkinsons-disease-100613848","NCT07271927","Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease","Evaluation Study of the Effects and Safety of Whole-Body Photobiomodulation Therapy on Motor and Cognitive Changes in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination\n* Adults aged 40 years or older\n* Individuals able to walk independently\n\nExclusion Criteria:\n\n* Individuals with severe cognitive impairment (Korean Mini-Mental State Examination \\[K-MMSE\\] score ≤ 9) making it difficult to understand and perform tasks\n* Patients with dementia other than Parkinson's disease dementia\n* Individuals with implanted medical or other electronic devices\n* Individuals with severe neuropsychiatric disorders\n* Individuals treated for alcohol dependence within 6 months prior to screening\n* Individuals with a history of suicide attempts\n* Individuals with a history of seizures\n* Individuals experiencing dyspnea while sitting at rest\n* Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses\n* Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid\n* Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months\n* Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods\n* Pregnant or breastfeeding women\n* Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above",{"count":243,"type":21},15,[24],"This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.",[247],"PARKINSON DISEASE (Disorder)",[249,250,134,251,252],"Photobiomodulation","Parkinson disease","motor function","light theraphy","2025-11-26",{"date":255,"type":34},"2025-12-09",{"date":257,"type":34},"2025-02-12",{"date":204,"type":21},{"name":40,"class":41},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":42},"100511456","effects-of-flumazenil-on-recovery-after-total-intravenous-anesthesia-with-remimazolam-100511456","NCT05939674","Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam","Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam in Elderly Patients Undergoing Hip Joint Surgery: a Prospective Randomized Controlled Study.","Inclusion Criteria:\n\n* Patients over 65 years old scheduled for hip joint surgery\n\nExclusion Criteria:\n\n* Patients with impaired consciousness or delirium before surgery\n* Patients who are hemodynamically unstable before surgery\n* Patients with a history of neurological or neuromuscular disorders or use of medications that affect neurological or neuromuscular function\n* Patients who have taken sedatives (anti-anxiety medications, antipsychotics, antidepressants, sleep aids) within the past 24 hours\n* Patients with known allergy to benzodiazepine, flumazenil\n* Patients with galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption\n* Patients with hypersensitivity to Dextran40\n* Patients who have been taking benzodiazepine for long term\n* Patients with end stage renal disease requiring hemodialysis\n* Patients with history of acute angle glaucoma\n* Patients with alcohol or substance dependence\n* ASA classification 4 or 5",{"count":268,"type":21},24,[24],"Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.",[272,273,274,275],"Flumazenil Adverse Reaction","Remimazolam","Hip Joint","Elderly Patients","2025-09-07",{"date":278,"type":34},"2025-09-12",{"date":280,"type":34},"2023-09-19",{"date":282,"type":21},"2026-06",{"name":40,"class":41},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":125,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":307},"100597588","phase-2-fluorescence-lymph-node-mapping-for-colon-cancer-surgery-100597588","NCT07060443","Fluorescence Lymph Node Mapping for Colon Cancer Surgery","Clinico-oncological Safety and Efficacy of Real-time Fluorescence Lymph Node Mapping (FLNM) in Laparoscopic and Robotic Right Hemicolectomy for Patients With Locally Advanced Right-sided Colon Cancer; Multicenter Phase II Open Labelled Randomized Controlled Trial","CONSTELLARE","Inclusion Criteria:\n\n1. Patients who over 19 years old, Under 85 years old\n2. Patient with locally advanced right colon cancer requiring D3 lymphadenectomy\n3. Colon cancer patients diagnosed with clinical stage cT3-4 N0 or cTany N1-2 before surgery\n4. Patient with right-sided colon cancer located in the cecum, ascending colon, flexure colon, and proximal transverse colon.\n5. Patients with American Society of Anesthesiology (ASA) I-III\n6. Patients who agreed to the research purpose and voluntarily gave informed consent\n\nExclusion Criteria:\n\n1. Patients with a history of allergy or side effects to sodium iodine\n2. Patients with colon cancer who have distant or peritoneal metastases\n3. Patients requiring emergency surgery due to colon obstruction or colon perforation\n4. Patients with inflammatory bowel disease not controlled by drug treatment\n5. Patients with concurrent cancer in other areas other than colon cancer\n6. Patients with a history of hereditary disease or coagulopathy at risk of bleeding\n7. Women who are pregnant or may be pregnant and lactating women\n8. Patients with chronic renal failure (e-GFR \\\u003C 15) or patients receiving dialysis at the time of screening\n9. Patients diagnosed with liver failure or with decreased consciousness due to hepatic encephalopathy\n10. Patients judged to have difficulty in smooth lymph perfusion due to heart disease (acute myocardial infarction, acute and chronic heart failure) within the past 6 months\n11. Patients unable to undergo general anesthesia\n12. Patients with American Society of Anesthesiology (ASA) IV or V\n13. Patients who do not wish to participate in this study\n14. Patients who are judged by the researcher to be unsuitable for participation in this clinical trial (Example: People with a life expectancy of less than 6 months, people expected to have low compliance with clinical trials, etc.)",{"count":293,"type":21},186,[295],"PHASE2","Fluorescence-guided surgery using indocyanine green can visualize the complex and diverse lymph node drainage structures for each patient and help determine the extent of dissection of the D3 lymph node tailored to the patient. However, since fluorescence lymph node mapping (FLNM) is still being conducted only at some institutions for research purposes and is limited to reporting the results of small-scale studies of patients, a large-scale multi-center study was conducted to verify the clinical-oncological effects of FLNM. Research is needed.\n\nTherefore, this study used real-time fluorescence lymph node mapping (FLNM) to determine the extent of D3 lymph node dissection when performing right hemicolectomy and D3 lymph node dissection in patients with locally advanced right-sided colon cancer and to safely remove extensive lymph nodes. We aim to evaluate whether the dissection procedure is safe and beneficial in terms of clinical oncology.",[298],"Right Hemicolectomy","2025-07-01",{"date":301,"type":34},"2025-07-11",{"date":303,"type":21},"2025-07-23",{"date":305,"type":21},"2030-12-31",{"name":40,"class":41},13,{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":18,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":323,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":336,"locationsCount":4},"100596067","hyaluronic-acid-for-prevention-of-post-intubation-sore-throat-and-hoarseness-100596067","NCT07040631","Hyaluronic Acid for Prevention of Post-Intubation Sore Throat and Hoarseness","Effect of Hyaluronic Acid on Post-Intubation Sore Throat and Hoarseness in Breast Cancer Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 19 to 80 years\n* Scheduled to undergo breast cancer surgery under general anesthesia with endotracheal intubation\n* American Society of Anesthesiologists (ASA) physical status I to III\n\nExclusion Criteria:\n\n* Mallampati classification of III or higher\n* Recent upper respiratory infection or symptoms of upper airway infection\n* Pre-existing laryngeal disease or chronic respiratory conditions (e.g., asthma, chronic bronchitis)\n* Current use of systemic steroids\n* Refusal to provide informed consent\n* Determined to be unsuitable for study participation by the investigator",{"count":316,"type":21},92,[24],"The goal of this clinical trial is to find out whether applying Endotra Gel, a hyaluronic acid-based gel, to the endotracheal tube can help reduce sore throat and hoarseness after surgery.\n\nThese symptoms are common after general anesthesia when a endotracheal tube is placed into the trachea. They can cause discomfort and affect patient recovery.\n\nThe main questions this study aims to answer are:\n\n* Does Endotra Gel reduce the chance of having a sore throat after surgery?\n* Does it help improve hoarseness or coughing after surgery?\n\nParticipants in this study will:\n\n* Undergo general anesthesia for breast cancer surgery\n* Be randomly assigned to one of two groups:\n\n  * One group will receive Endotra Gel applied to the endotracheal tube before intubation\n  * The other group will have standard care with no gel\n* Be monitored for sore throat, hoarseness, and coughing right after surgery and on the day after surgery\n* Answer questions about their symptoms and satisfaction with their recovery The results will help researchers learn whether using Endotra Gel during intubation can improve patient comfort and reduce airway irritation after surgery.",[320,321,322,55],"Breast Cancer","Postoperative Sore Throat, Cough, Hoarseness","Endotracheal Intubation",[324,325,326,322,327,328,329],"Postoperative Sore Throat","Hyaluronic Acid","Lubricating Gel","hoarseness","breast cancer surgery","randomized controlled trial","2025-06-24",{"date":332,"type":34},"2025-06-27",{"date":334,"type":21},"2025-06",{"date":183,"type":21},{"name":40,"class":41},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":4,"enrollmentInfo":345,"targetDuration":346,"studyType":105,"phases":4,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":356,"locationsCount":4},"100571370","evaluation-of-gait-impairment-and-correlation-in-patients-with-dcm-100571370","NCT06719375","Evaluation of Gait Impairment and Correlation in Patients With DCM","Evaluation of Gait Impairment and Correlation With Clinical Assessment Tools Before and After Surgery in Patients With Cervical Myelopathy Using Inertial Sensors","DCM-HFIMU","Inclusion Criteria:\n\n* Age 18 years or older.\n* Able to communicate and provide informed consent.\n* Capable of walking at least 3 meters without assistance from others or walking aids.\n* No prior surgical treatment for cervical myelopathy.\n* Lower limb motor function score of 2 or higher on the mJOA scale.\n\nExclusion Criteria:\n\n* Presence of severe respiratory or cardiac conditions that impede safe walking.\n* Musculoskeletal issues, such as spinal deformities, affecting gait.\n* History of neurological disorders affecting gait, including peripheral nerve injury, joint stiffness, stroke, traumatic brain injury, myelitis, or Parkinson's disease.\n* Prior orthopedic or neurosurgical interventions that could impact gait.\n* Cervical conditions resulting from trauma (acute fracture or acute disc herniation), tumor, or infection.",{"count":104,"type":21},"50 Days","This study aims to evaluate gait impairment in patients with Degenerative Cervical Myelopathy (DCM) before and after surgery using an inertial measurement unit (IMU) sensor. By comparing IMU-derived gait parameters with traditional clinical assessment tools (e.g., Modified Ashworth Scale, mJOA, and GRASSP), the study seeks to determine the effectiveness and reliability of IMU sensors for assessing and monitoring gait improvement and neurological recovery in DCM patients. This study is conducted outside the United States and does not involve interventions or devices subject to U.S. FDA regulation.",[349],"Myelopathy Cervical","2025-06-20",{"date":352,"type":34},"2025-06-25",{"date":354,"type":21},"2025-10-01",{"date":204,"type":21},{"name":40,"class":41},{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":214,"sex":16,"minAge":364,"maxAge":125,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":42},"100593841","phospholipid-rich-dairy-extract-for-cognitive-function-100593841","NCT07011680","Phospholipid-rich Dairy Extract for Cognitive Function","A 12-week Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Dietary Phospholipid-rich Dairy Milk Extract on Cognitive Function Improvement in Adults With Mild Cognitive Impairment.","Inclusion Criteria:\n\n* Age: Adults aged 55-85 years (inclusive), both male and female\n* Global Deterioration Scale (GDS) score of 2-3:\n\nGDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment\n\n* Absence of dementia according to established diagnostic criteria\n* Ability to read Korean\n\nExclusion Criteria:\n\n* Severe medical conditions within the past 6 months: History of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignancy (Note: Participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion)\n* Cognitive impairment-associated diseases: Dementia, Parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline Uncontrolled hypertension: Blood pressure ≥160\u002F100 mmHg (measured after 10 minutes of rest)\n* Poor glycemic control: Fasting blood glucose ≥160 mg\u002FdL in diabetic patients\n* Uncontrolled thyroid dysfunction: Currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism\n* Renal impairment: Serum creatinine ≥2 times the upper limit of normal for the institution\n* Hepatic impairment: AST or ALT ≥2 times the upper limit of normal for the institution\n* Severe gastrointestinal symptoms: Complaints of severe heartburn, dyspepsia, or other gastrointestinal distress\n* Medications affecting cognitive function within the past month: Use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities\n* Other clinical trial participation: Participation in other drug clinical trials within the past month or planned participation during the study period\n* Alcohol abuse\n* Food allergies: Known allergic reactions to study product components\n* Investigator discretion: Any other condition deemed inappropriate for study participation by the investigator","55 Years",{"count":127,"type":21},[24],"This clinical trial aims to determine whether dietary phospholipid-rich dairy milk extract improves cognitive function in adults with mild cognitive impairment and to assess its safety.\n\nThe main questions are:\n\n* Does dietary phospholipid-rich dairy milk extract improve cognitive function in participants?\n* What side effects occur when participants take phospholipid-rich dairy milk extract?",[369,132],"Cognitive Function","2025-06-09",{"date":372,"type":34},"2025-06-12",{"date":374,"type":34},"2025-01-07",{"date":67,"type":21},{"name":40,"class":41},{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":4},"100585857","comparison-of-sevoflurane-and-propofol-on-ani-100585857","NCT06907823","Comparison of Sevoflurane and Propofol on ANI","Comparison of Sevoflurane and Propofol on ANI in Patients Undergoing General Anesthesia: a Prospective Randomized Controlled Study","Inclusion Criteria:\n\n* American society of anesthesiologists physical status class I or II\n\nExclusion Criteria:\n\n* history of drugs that can affect the central nervous system and autonomic nervous system, such as anticholinergics, betablockers, antidepressants..etc.\n* history of allergic reaction to sevoflurane and\u002For propofol\n* history of and\u002For family history of malignant hyperthermia\n* neurodegenerative disorder\n* psychiatric disorder\n* arrhythmia\n* diabetes mellitus\n* drug abuse history",{"count":104,"type":21},[24],"The goal of this clinical trial is to compare the effect of sevoflurane and propofol on analgesia nociception index(ANI) in patients undergoing general anesthesia. The main question it aims to answer is whether propofol anesthesia results in lesser ANI change to a nociceptive stimulation compared to sevoflurane.",[388,59,57],"Propofol","2025-06-08",{"date":391,"type":34},"2025-06-10",{"date":393,"type":21},"2025-06-30",{"date":204,"type":21},{"name":40,"class":41},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":214,"sex":16,"minAge":49,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":42},"100564536","meu-cinn-for-gastric-mucosal-health-in-adults-with-functional-dyspepsia-100564536","NCT06630455","Meu-cinn for Gastric Mucosal Health in Adults With Functional Dyspepsia","Effects of Meu-cinn on Promoting Gastric Mucosal Health in Adults With Functional Dyspepsia: A Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* Rome IV-based functional dyspepsia-\n\nExclusion Criteria:\n\n* Patients with gastrointestinal symptoms requiring immediate drug treatment.\n* Individuals with a history of hypersecretory gastric disorders like Zollinger-Ellison syndrome.\n* Individuals who received Helicobacter pylori eradication therapy within 4 weeks prior to the trial.\n* Individuals who have taken nonsteroidal anti-inflammatory drugs, steroids, antibiotics, aspirin, antithrombotic agents, or acid suppressants within the last month.\n* Individuals with a history of upper gastrointestinal surgery, stricture, bleeding, or procedures like esophageal dilation or mucosal resection within the last year.\n* Individuals with gastric ulcers (active or healing), duodenal ulcers (active or healing), reflux esophagitis (LA grade A or higher), or malignant tumors identified within the last 6 months through endoscopy.\n* Patients with uncontrolled hypertension (resting BP ≥160\u002F100 mmHg).\n* Patients with uncontrolled diabetes (fasting glucose ≥160 mg\u002FdL).\n* Individuals with creatinine levels ≥ 2 times the upper limit of normal at the research institution.\n* Individuals with aspartate aminotransferase or alanine aminotransferase levels ≥ 2 times the upper limit of normal at the research institution.\n* Alcohol abusers.\n* Individuals taking medications for psychiatric disorders (except those taking intermittent medication for sleep disorders).\n* Pregnant or breastfeeding women or those planning to become pregnant during the clinical trial period.\n* Individuals with allergies to any components of the study foods.\n* Individuals who participated in or plan to participate in another drug clinical trial within the last month.\n* Individuals deemed unsuitable for the study by the investigator for other reasons.","70 Years",{"count":127,"type":21},[24],"This clinical trial aims to determine whether Meu-cinn promotes gastric mucosal health in adults with functional dyspepsia and to assess its safety.\n\nThe main questions are:\n\n* Does Meu-cinn promote gastric mucosal health in participants?\n* What side effects occur when participants take Meu-cinn?",[408],"Functioanl Dyspepsia","2025-06-01",{"date":411,"type":34},"2025-06-03",{"date":413,"type":34},"2024-12-04",{"date":204,"type":21},{"name":40,"class":41},{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":214,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":42},"100387089","effect-of-fermented-protaetia-brevitarsis-seulensis-powder-on-alcohol-induced-liver-disease-100387089","NCT04320199","Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease","Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Gamma-glutamyl transferase ranging from upper limit of reference to four times of upper limit\n\nExclusion Criteria:\n\n* Abnormal liver or renal function (i.e., serum aminotransferase activity \\> 3 times of upper limit of reference range and serum creatinine concentrations \\> 1.2 mg\u002FdL)\n* Diabetes (diagnosed clinically or fasting glucose level \\> 126 mg\u002FdL)\n* History of viral hepatitis or cancer\n* Uncontrolled hypertension\n* History of serious cardiac disease such as angina or myocardial infarction\n* History of gastrectomy\n* History of medication for psychiatric disease\n* Administration of oriental medicine including herbs within the past 4 weeks",{"count":104,"type":21},[24],"The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Fermented Protaetia brevitarsis seulensis powder on Alcohol-induced Liver Disease in adults for 8 weeks.",[427],"Alcoholic Liver Disease",{"date":429,"type":34},"2025-06-04",{"date":431,"type":34},"2020-01-01",{"date":204,"type":21},{"name":40,"class":41},{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":214,"sex":16,"minAge":49,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":22,"phases":444,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":42},"100345295","effect-of-panax-ginseng-ca-mey-extract-on-liver-function-in-adults-100345295","NCT03775837","Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults","Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults: a Randomized, Double-blinded, Placebo-controlled Trial","Inclusion Criteria:\n\n* ALT ranging from upper limit of reference to three times of upper limit\n\nExclusion Criteria:\n\n* Abnormal liver or renal function (i.e., serum aminotransferase activity \\> 3 times of upper limit of reference range and serum creatinine concentrations \\> 1.2 mg\u002FdL)\n* Diabetes (diagnosed clinically or fasting glucose level \\> 126 mg\u002FdL)\n* History of viral hepatitis or cancer\n* Uncontrolled hypertension\n* History of serious cardiac disease such as angina or myocardial infarction\n* History of gastrectomy\n* History of medication for psychiatric disease\n* Administration of oriental medicine including herbs within the past 4 weeks","75 Years",{"count":443,"type":21},60,[24],"The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Panax Ginseng C.A. Mey Extract on liver function in adults for 8 weeks.",[447],"Liver Diseases",{"date":429,"type":34},{"date":450,"type":34},"2018-12-01",{"date":204,"type":21},{"name":40,"class":41},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":460,"enrollmentInfo":461,"targetDuration":463,"studyType":105,"phases":4,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":42},"100584284","deep-sedation-with-pre-emptive-endotracheal-intubation-for-advanced-bronchoscopy-procedures-100584284","NCT06887335","Deep Sedation With Pre-emptive Endotracheal Intubation for Advanced Bronchoscopy Procedures","An Observational Prospective Study on the Safety and Feasibility of Deep Sedation Under Proceduralist Direction With Pre-emptive Endotracheal Intubation for Advanced Bronchoscopy Procedures","Inclusion Criteria:\n\n* Patients requiring a bronchoscopy-assisted procedure for diagnostic or therapeutic purposes\n* Individuals who voluntarily consent to participate in the clinical study and sign a written informed consent form\n\nExclusion Criteria:\n\n* Patients who have experienced acute myocardial infarction or acute stroke within the past six weeks\n* Patients with contraindications to bronchoscopy (e.g., severe respiratory or cardiovascular comorbidities)\n* Patients with a history of allergy to benzodiazepines, propofol, fentanyl, or flumazenil\n* Patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n* Patients with a severe hypersensitivity reaction to dextran 40\n* Patients with a history of acute angle-closure glaucoma\n* Pregnant women\n* Prisoners\n* Patients with psychiatric disorders\n* Patients classified as ASA Physical Status IV or V by the American Society of Anesthesiologists (ASA)\n* Any other patients deemed unsuitable for the clinical study by the investigator","90 Years",{"count":462,"type":21},203,"1 Week","Bronchoscopy is crucial for diagnosing and treating respiratory diseases and is recommended under sedation. Deep sedation improves patient comfort and procedural efficiency, especially in complex cases, by reducing movement and coughing. However, it carries risks of respiratory depression and airway obstruction, potentially requiring premature termination or urgent intubation. Determining the optimal timing for intubation can be challenging despite proper monitoring. To enhance safety, the investigator has performed bronchoscopy under deep sedation with preemptive intubation for years, sharing this experience with other hospitals. This study aims to evaluate its safety and feasibility through a multicenter prospective observational approach.",[466],"Lung Diseases","2025-05-27",{"date":469,"type":34},"2025-05-31",{"date":471,"type":34},"2025-04-08",{"date":67,"type":21},{"name":40,"class":41},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":42},"100570802","comparison-of-the-efficacy-and-safety-of-mirogabalin-and-duloxetine-in-chemotherapy-induced-peripheral-neuropathy-in-a-randomized-controlled-trial-a-quality-of-life-study-in-cancer-survivors-100570802","NCT06711978","Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors","Inclusion Criteria:\n\n* Cancer survivors aged 19 years or older.\n* Peripheral, symmetrical pain in both feet occurring within 12 weeks of initiating chemotherapy with taxane or platinum agents (or their combination).\n* Patients experiencing at least grade 2 peripheral neuropathy as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, with an average pain intensity of 4 or higher on the Numerical Rating Scale (NRS) during the past week, following the completion of chemotherapy.\n* Concurrent use of selected analgesics (acetaminophen, nonsteroidal anti-inflammatory drugs \\[NSAIDs\\]) is permitted if the following conditions are met:\n\n  1. No new analgesics are introduced.\n  2. Current analgesics are not discontinued.\n  3. The total weekly 24-hour dose of analgesics does not vary by more than 10% during the 2 weeks prior to enrollment.\n* Ongoing treatment for peripheral neuropathy or neuropathic pain must be discontinued at least 7 days before randomization\n\nExclusion Criteria:\n\n* Patients with a prior diagnosis of peripheral neuropathy due to diabetes, trauma, alcohol abuse, compression, or other causes, or those with a previously diagnosed central nervous system disorder. (Patients with pre-existing diabetes or thyroid disease who had no symptoms of peripheral neuropathy, such as numbness or tingling in the hands or feet, before chemotherapy may be included.)\n* Patients with significant psychiatric disorders, such as severe depression, bipolar disorder, or suicidal ideation.\n* Pregnant or breastfeeding patients.\n* Patients with a history of prior treatment with other neurotoxic chemotherapeutic agents.\n* Patients with renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin) or hepatic dysfunction.\n* Patients with planned surgical procedures within 4 weeks of enrollment.",{"count":195,"type":21},[24],"To conduct a two-arm, parallel, prospective, randomized controlled, open-label trial to compare the efficacy of the novel drug mirogabalin with the conventional treatment duloxetine in reducing pain associated with chemotherapy-induced peripheral neuropathy (CIPN).\n\nThere will be a difference in pain reduction after 4 weeks of treatment between the mirogabalin group and the duloxetine group in patients with chemotherapy-induced peripheral neuropathy (CIPN).\n\nParticipants will:\n\n* Take drug duloxetine or a mirogabalin every day for 4 weeks.\n* Visit the clinic once every 2 weeks for checkups and tests",[484,485,486,487,488],"CIPN","CIPN - Chemotherapy-Induced Peripheral Neuropathy","CIPN in Adjuvant Breast Cancer Patients","Duloxetine","Mirogabalin","2024-11-26",{"date":491,"type":34},"2024-12-02",{"date":493,"type":21},"2024-12-01",{"date":393,"type":21},{"name":40,"class":41},{"id":497,"slug":498,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":214,"sex":16,"minAge":49,"maxAge":18,"enrollmentInfo":502,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":513,"leadSponsor":514,"locationsCount":4},"100570249","investigation-of-the-possibility-of-determining-cerebrovascular-disease-based-on-hemodynamic-information-of-localized-brain-regions-100570249","NCT06704789","Investigation of the Possibility of Determining Cerebrovascular Disease Based on Hemodynamic Information of Localized Brain Regions","Inclusion Criteria :\n\n1. For Hemorrhagic Stroke Patients :\n\n   * Adults aged between 19 and 80 years.\n   * Diagnosed with hemorrhagic stroke through clinical observation and neuroimaging.\n   * First-time hemorrhagic stroke patients.\n   * Hemorrhagic stroke onset between 2 weeks and 12 months prior to screening.\n   * Hemorrhagic lesion located in the cortex or subcortex.\n   * Not taking medications that could affect brain hemodynamics, such as - antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n2. For Ischemic Stroke Patients :\n\n   * Adults aged between 19 and 80 years.\n   * Diagnosed with ischemic stroke through clinical observation and neuroimaging.\n   * First-time ischemic stroke patients.\n   * Ischemic stroke onset between 2 weeks and 12 months prior to screening.\n   * Ischemic lesion located in the cortex or subcortex.\n   * Not taking medications that could affect brain hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n3. For Healthy Adults :\n\n   * Adults aged between 19 and 80 years.\n   * No history of stroke or transient ischemic attack (TIA).\n   * No stroke risk factors such as hypertension, diabetes, or hyperlipidemia.\n   * No chronic diseases (e.g., cardiovascular disease, chronic kidney disease, chronic lung disease).\n   * No psychiatric conditions (e.g., depression, schizophrenia).\n   * Not taking medications that could affect brain hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n\nExclusion Criteria :\n\n* History of head trauma in the past 6 months.\n* Ongoing severe chronic diseases (e.g., heart failure, chronic kidney disease, chronic lung disease).\n* Severe psychiatric disorders such as schizophrenia, major depression, or bipolar disorder.\n* Use of medications that could influence brain hemodynamics (e.g., antihypertensives, anticoagulants, antiplatelets, or antidepressants).\n* Participation in a study and use of experimental drugs within the past 30 days.\n* Pregnant or breastfeeding women.\n* Major surgery in the past 6 months.\n* Acute infections or inflammatory diseases.\n* Cognitive impairment or dementia.\n* Neurological disorders.\n* Inability to understand the study procedures or unwillingness to provide voluntary consent.\n* Any other clinical concerns deemed inappropriate for participation by the principal investigator or study team.",{"count":503,"type":21},90,"The purpose of this study is to compare hemodynamic information from localized brain regions between stroke patients and healthy adults using brain activity data (fNIRS and EEG) and to assess the accuracy of early stroke diagnosis and classification predictions.",[506,507,508,509],"EEG","FNIRS","Stroke","Normal","2024-11-21",{"date":489,"type":34},{"date":493,"type":21},{"date":204,"type":21},{"name":40,"class":41},{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":214,"sex":16,"minAge":49,"maxAge":18,"enrollmentInfo":521,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":529,"leadSponsor":530,"locationsCount":4},"100570012","exploratory-study-on-artifact-denoising-of-cerebral-blood-flow-and-eeg-data-in-ambulance-settings-100570012","NCT06701708","Exploratory Study on Artifact Denoising of Cerebral Blood Flow and EEG Data in Ambulance Settings","Inclusion Criteria:\n\n* Healthy adults aged 19 to 80 years.\n* Individuals without chronic diseases (e.g., Stage 2 hypertension, cardiovascular disease, chronic kidney disease, chronic pulmonary disease, etc.).\n* Individuals without mental health disorders (e.g., depression, schizophrenia, etc.).\n* Individuals not taking medications that could affect cerebral hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, antidepressants, etc.\n\nIndividuals who can read and understand the participant information and consent form and have sufficient language ability to respond to questionnaires.\n\n\\- Individuals who voluntarily decide to participate in the clinical study, provide written consent on the participant consent form, and are able to participate throughout the entire duration of the clinical study.\n\nExclusion Criteria:\n\n* Individuals who have experienced head trauma in the past 6 months.\n* Individuals with ongoing severe chronic diseases (e.g., heart failure, chronic kidney disease, chronic pulmonary disease, etc.).\n* Individuals with severe mental health disorders such as schizophrenia, severe depression, bipolar disorder, etc.\n* Individuals currently taking medications that may affect the study (e.g., antihypertensives, anticoagulants, antiplatelets, antidepressants, etc.).\n* Individuals who have participated in a clinical trial and taken experimental drugs within the past 30 days.\n* Women who are pregnant or breastfeeding.\n* Individuals who have undergone major surgery in the past 6 months.\n* Individuals with acute infections or inflammatory diseases.\n* Individuals with cognitive impairment or dementia.\n* Individuals with neurological disorders.\n* Individuals who lack understanding of the study procedures or who have not voluntarily consented to participate.\n* Individuals with clinically significant findings that the study principal investigator or responsible medical personnel determines to be inappropriate for participation in this study.",{"count":522,"type":21},20,"The purpose is to assess the extent of digital noise occurring during the measurement of cerebral blood flow and EEG in healthy adults within an ambulance setting and to explore the possibility of identifying and correcting abnormal patterns.",[509,506,507],"2024-11-20",{"date":527,"type":34},"2024-11-22",{"date":493,"type":21},{"date":204,"type":21},{"name":40,"class":41},{"id":532,"slug":533,"hasResults":11,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":11,"sex":16,"minAge":441,"maxAge":538,"enrollmentInfo":539,"targetDuration":541,"studyType":105,"phases":4,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":551,"locationsCount":42},"100560496","the-study-to-evaluate-the-safety-and-efficacy-of-the-onyx-family-100560496","NCT06577896","The Study to Evaluate the Safety and Efficacy of the Onyx Family","Safety and Efficacy of 1-month Dual Antiplatelet Therapy in High Bleeding and Ischemic Risk Elderly Patients With Coronary Artery Disease After Implantation of Zotarolimus-eluting Coronary Stent System (Onyx Family, Medtronic, Minneapolis, MN); A Multicenter, Prospective, Observational Study","Inclusion Criteria:\n\n* Aged 75 or more.\n* Eligible for interventional procedures.\n* Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%.\n* Able to take antiplatelets for at least 1 months after the procedure.\n* Patients who underwent coronary artery procedures with ZES (Medtronic, Minneapolis, MN, Onyx™ family) stent.\n\nExclusion Criteria:\n\n* The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus, and contrast media (patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \\[eg, rash\\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled).\n* Patients with active pathologic bleeding.\n* Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.\n* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia).\n* Noncardiac comorbid conditions are present with life expectancy \\<1 year or that may result in protocol noncompliance (per site investigator\\'s medical judgment).\n* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.","100 Years",{"count":540,"type":21},500,"1 Year","Observation of the safety and efficacy of 1-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using Onyx family stents in elderly patients aged 75 years or older",[544],"Coronary Artery Disease","2024-09-05",{"date":547,"type":34},"2024-09-19",{"date":549,"type":34},"2022-06-09",{"date":67,"type":21},{"name":40,"class":41},{"id":553,"slug":554,"hasResults":11,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":560,"enrollmentInfo":561,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":42},"100519295","effect-of-local-warming-for-arterial-catheterization-in-pediatric-anesthesia-100519295","NCT06041685","Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia","Effect of Local Warming for Arterial Catheterization in Pediatric Cardiac Surgery: A Prospective Randomized Controlled Study","WARM-PA","Inclusion Criteria:\n\n* aged ≤ 2 years\n* cardiac surgery with peripheral artery catheterization\n\nExclusion Criteria:\n\n* unstable vital signs\n* pre-existing arterial catheter (exception of umbilical artery catheterization)","2 Years",{"count":562,"type":21},126,[24],"The increase in internal diameter (ID) and cross-sectional area (CSA) may facilitate better arterial catheterization. Since an increase in body temperature can cause peripheral vasodilation, we aimed to determine if local warming of the radial artery (RA) catheterization site could improve the success rate of catheterization in pediatric patients.",[566],"Congenital Heart Disease","2024-08-09",{"date":569,"type":34},"2024-08-12",{"date":571,"type":34},"2023-09-22",{"date":204,"type":21},{"name":40,"class":41},""]